AIM ImmunoTech Inc. (NYSE: AIM) reported a net loss of $3.8 million for the second quarter ended June 30, 2026, widening from a $2.8 million loss in the same period of 2025. The company’s earnings per share (EPS) of $(0.43) missed the analyst consensus estimate of $(0.18) by 138.89 percent. Despite the widened loss, AIM strengthened its liquidity position with $9.9 million in cash and cash equivalents as of June 30, 2026, up from approximately $3.0 million at the end of December 2025.

The quarterly EPS figure represented an 88.32 percent increase over losses of $(3.68) per share from the same period last year, driven by a significant reduction in share count or other capital structure changes not detailed in the filing but implied by the divergence between total net loss and per-share metrics. Revenue from operations increased slightly to $26.000 thousand, up 4.00 percent from $25.000 thousand in Q2 2025. This marginal top-line growth underscores the company’s pre-commercial status, where operational focus remains on clinical development rather than product sales.

Financial Performance

Research and development expenses declined to approximately $589,000 in Q2 2026, down from $1.2 million in the year-ago period. However, general and administrative expenses increased to approximately $2.9 million from $1.5 million in the same period of 2025. The divergence between R&D savings and G&A growth reflects the company's focus on scaling operational infrastructure to support upcoming Phase 3 trial preparations.

Clinical Milestones

AIM completed patient enrollment and Ampligen dosing in the ongoing Phase 2 DURIPANC study. This trial evaluates Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in metastatic pancreatic cancer. The company has engaged Thermo Fisher Scientific’s PPD clinical research business to support the study design of a planned pivotal Phase 3 clinical trial in metastatic pancreatic cancer.

CEO Thomas K. Equels stated that the company anticipates DURIPANC data on clinical benefit in Q1 2027 and Overall Survival data in Q3 2027. These data points are critical for the foundation of the pivotal Phase 3 clinical trial design. Previous findings from Ampligen’s Dutch-government approved Named Patient Program showed a median Overall Survival of 34.8 months compared to 12.5 months for historical controls in late-stage pancreatic cancer patients.

What the Numbers Show

The widening net loss despite improved per-share metrics highlights the impact of capital structure adjustments on reported profitability figures. While R&D costs were successfully curtailed, the sharp rise in G&A expenses suggests increased overhead associated with preparing for larger-scale trials. The minimal revenue growth confirms that near-term cash burn will remain dependent on external funding or existing cash reserves, which currently support operations through early 2027.

AIM ImmunoTech Inc. (NYSE: AIM) announced that the final subject in its Phase 2 DURIPANC clinical trial has received their last dose of Ampligen (rintatolimod) under the study protocol. This milestone was reached ahead of schedule, marking a critical inflection point for the company’s lead candidate in treating metastatic pancreatic cancer. The trial evaluates Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab). This completion sets the stage for data analysis, with Primary Endpoint analysis expected to begin in December 2026 and topline results anticipated in Q1 2027.

The primary endpoint is defined as the Clinical Benefit Rate (CBR), which measures the proportion of patients achieving stable disease, partial response, or complete response at 24 weeks following the initiation of combination therapy. DURIPANC is an investigator-initiated, exploratory, open-label, single-center Phase 2 study representing a joint collaboration between AIM ImmunoTech, AstraZeneca, and Erasmus Medical Center in the Netherlands.

Trial Structure and Secondary Endpoints

Beyond the primary CBR endpoint, the study includes several secondary and exploratory objectives aimed at understanding long-term outcomes and patient stratification.

Analysis of the Overall Survival endpoint is expected to begin in June 2027, or 49 weeks after the final subject received their first dose. Overall survival is considered the gold standard in oncology trials. Additionally, immune profiling analysis aims to identify subsets of future pancreatic cancer patients likely to experience the best clinical benefit and overall survival results, which could be critical for designing a pivotal Phase 3 clinical trial.

Historical Context and Biomarker Insights

AIM referenced encouraging results from a Dutch Ministry of Health-approved Named Patient Program that provided more than 50 post-standard-of-care pancreatic cancer patients with access to Ampligen as a monotherapy. While this program was not designed to assess efficacy and findings were exploratory, biomarker stratification analysis showed promising trends. In the patient subset with immune biomarker Neutrophil/Lymphocyte ratios less than 4.5, Ampligen achieved a median Overall Survival of 34.8 months compared to 12.5 months for historical controls — an improvement of 22.3 months.

What the Numbers Show

The significant divergence in median Overall Survival between the specific biomarker subset (NLR < 4.5) and historical controls highlights the potential importance of patient stratification. While the Named Patient Program data is exploratory and not efficacy-determining, the 22.3-month improvement suggests that immune profiling could be a key differentiator in future Phase 3 trial design. This aligns with the DURIPANC trial’s secondary objective of exploring immune-monitoring using tissue biopsies and peripheral immune profiling.

Thomas Equels, Chief Executive Officer of AIM ImmunoTech, stated that while the improvement in overall survival seen in the Named Patient Program is an important signal, it requires Phase 2 and Phase 3 clinical trials to verify efficacy and support statistical validity. He noted that executing DURIPANC milestones ahead of schedule affirms the company’s commitment to analyzing biomarker stratifications as it designs a pivotal Phase 3 trial to move Ampligen toward eventual submission of a New Drug Application.

Regulatory and Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties, including timing of clinical trial evaluations, regulatory approvals, and funding adequacy. Actual results may differ materially from those expressed or implied. Investors are directed to the Company’s Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC for a detailed discussion of risk factors.